Cancer Drug Shows Increased Risk of Death When Used With Other Therapies
Stony Brook MedicineCancer patients treated with the chemotherapy agent bevacizumab (Avastin) may be at an increased risk of treatment-related death when the drug is used in combination with other therapies.